ZURICHNovartis AG is distancing itself from the era of Daniel Vasella the former chairman whose controversial exit package blemished the Swiss pharmaceutical companys image when he stepped down a year ago  In November Novartis struck a  billion deal to sell the bulk of its diagnostics business to a Spanish company the first indication it would slim down the sprawling portfolio of businesses Dr Vasella had assembled over two decades A month later Novartis said it was scrapping plans to build a training center
  